Leukemia Limfositik Kronis (CLL)

01Pathophysiology

CLL arises from a clonal population of mature but functionally defective B lymphocytes that co-express CD5, a marker typically found on T cells. The fundamental problem is not uncontrolled proliferation but rather resistance to programmed cell death (apoptosis). The malignant B cells overexpress BCL-2, an anti-apoptotic protein that allows these cells to survive far beyond their normal lifespan. This is why the disease accumulates slowly and tends to present insidiously in older adults rather than acutely.

Because these B cells are immunologically incompetent, they cannot produce functional antibodies. This leads to hypogammaglobulinemia, which is the primary reason CLL patients suffer from recurrent sinopulmonary and bacterial infections. The immune dysfunction extends beyond antibody deficiency: CLL cells actively suppress normal immune surveillance, creating a state of generalized immune dysregulation.

A hallmark complication is autoimmune cytopenias. The dysfunctional immune system produces autoantibodies against the patient's own blood cells, most commonly causing warm autoimmune hemolytic anemia (AIHA) with a positive direct Coombs test. Immune thrombocytopenia (ITP) can also occur. This is a frequently tested concept: when a CLL patient develops sudden anemia with reticulocytosis and elevated LDH/indirect bilirubin, think autoimmune hemolysis, not disease progression.

The malignant lymphocytes infiltrate the bone marrow, lymph nodes, spleen, and liver. Marrow infiltration eventually crowds out normal hematopoiesis, producing cytopenias (anemia, thrombocytopenia, neutropenia) in advanced stages. Lymph node involvement produces the characteristic painless, generalized lymphadenopathy. Splenic infiltration causes splenomegaly, leading to early satiety and left upper quadrant discomfort.

In approximately 2 to 10% of cases, CLL undergoes Richter transformation, an aggressive conversion into diffuse large B-cell lymphoma (DLBCL) or, rarely, Hodgkin lymphoma. This should be suspected when a CLL patient develops rapidly enlarging lymph nodes, markedly elevated LDH, new B symptoms, or sudden clinical deterioration. Richter transformation carries a poor prognosis and requires immediate tissue biopsy for confirmation.

02Classification and Clinical Manifestation

CLL is staged using two complementary systems. The Rai staging system (used predominantly in the United States) and the Binet staging system (used predominantly in Europe) both stratify patients by disease burden and predict survival.

Rai Staging System

Binet Staging System

Stages III and IV in the Rai system (or Stage C in Binet) define high-risk disease because the cytopenias reflect bone marrow failure from tumor infiltration. These stages always warrant treatment.

Clinical Manifestations by System

03Diagnostic Workup

The diagnosis of CLL begins with a CBC that reveals an unexpectedly high white blood cell count driven by lymphocytosis. This is often an incidental finding in an otherwise well-appearing elderly patient. The sustained absolute lymphocyte count must be $\ge 5\times {10}^9\mathrm{/}\text{L}\backslash geq\; 5\; \backslash times\; 10^9/\backslash text\{L\}$ for at least 3 months to meet diagnostic criteria.

The peripheral blood smear is the next step. It shows a monotonous population of small, mature-appearing lymphocytes. The hallmark finding is smudge cells (also called basket cells), which are artifacts created when the fragile CLL lymphocytes are crushed during the smear preparation. Smudge cells are not pathognomonic but are highly suggestive in the right clinical context.

Flow cytometry of peripheral blood is the confirmatory test and is sufficient to establish the diagnosis in nearly all cases. The immunophenotype is distinctive: the cells co-express the B-cell markers CD19 and CD20 (characteristically dim) alongside the T-cell marker CD5. They also express CD23, which is a critical discriminator from mantle cell lymphoma (CD5+ but CD23 negative). Surface immunoglobulin expression is dim, and light chain restriction (kappa or lambda) confirms clonality.

A crucial exam point: bone marrow biopsy is NOT required to diagnose CLL. Flow cytometry on peripheral blood is sufficient. Marrow biopsy is reserved for evaluating unexplained cytopenias or assessing response to treatment in clinical trials.

Cytogenetic analysis with FISH is performed not for diagnosis but for prognostic stratification and treatment planning. The single most important genetic abnormality to know is del(17p) or TP53 mutation, which confers resistance to chemoimmunotherapy and mandates the use of targeted agents (BTK or BCL-2 inhibitors). Del(13q) as the sole abnormality carries the best prognosis, while del(11q) and unmutated IGHV status predict more aggressive disease.

04Management and Treatment

The single most tested management concept in CLL is "watch and wait." Early-stage, asymptomatic CLL does not benefit from early treatment. Multiple randomized trials have demonstrated that treating asymptomatic patients does not improve survival and only exposes them to unnecessary toxicity. The "next best step" for a newly diagnosed, asymptomatic CLL patient is observation with serial monitoring.

Indications to begin treatment (iwCLL criteria) include:

• Progressive marrow failure (worsening anemia or thrombocytopenia)

• Progressive or symptomatic splenomegaly (> 6 cm below the costal margin)

• Progressive or bulky lymphadenopathy (> 10 cm)

• Progressive lymphocytosis with a lymphocyte doubling time < 6 months

• Constitutional symptoms (B symptoms)

• Autoimmune cytopenias refractory to corticosteroids

When treatment is indicated, the landscape has shifted from traditional chemoimmunotherapy toward targeted therapies.

Ibrutinib (420 mg orally once daily, taken continuously until progression or intolerance) is a first-generation Bruton tyrosine kinase (BTK) inhibitor. It blocks the B-cell receptor signaling pathway that CLL cells rely on for survival. It is effective across all cytogenetic risk groups, including del(17p). Key side effects to know for the exam: atrial fibrillation, bleeding (inhibits collagen-mediated platelet aggregation), hypertension, and arthralgias. Acalabrutinib and zanubrutinib are newer-generation BTK inhibitors with improved selectivity and fewer off-target cardiac effects.

Venetoclax (target dose 400 mg orally daily after a 5-week dose ramp-up) is a BCL-2 inhibitor that directly promotes apoptosis in CLL cells. Because it can cause rapid tumor lysis, a gradual dose escalation with tumor lysis syndrome (TLS) prophylaxis (aggressive hydration, allopurinol or rasburicase, electrolyte monitoring) is mandatory. Venetoclax is commonly paired with obinutuzumab (anti-CD20 antibody) for a fixed-duration regimen (typically 12 months), which is attractive because the patient can stop treatment.

FCR (fludarabine 25 mg/m${}^2^2$ IV days 1-3, cyclophosphamide 250 mg/m${}^2^2$ IV days 1-3, rituximab 375-500 mg/m${}^2^2$ IV day 1, every 28 days for 6 cycles) remains an option for young, fit patients with mutated IGHV and without del(17p), where it can achieve durable long-term remissions. However, its use is declining in favor of targeted therapies due to cumulative myelosuppression and the risk of secondary myelodysplastic syndrome/acute myeloid leukemia.

For autoimmune complications, the treatment targets the autoimmune process itself. Corticosteroids are first-line for warm AIHA and ITP. Rituximab can be added for refractory cases. Importantly, autoimmune cytopenias alone (without other indications) do not necessarily mandate CLL-directed therapy.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students get CLL questions wrong falls into three categories.

First, treating an asymptomatic patient. A vignette will describe an elderly patient with incidental lymphocytosis, smudge cells, and confirmed CLL on flow cytometry, then ask for the next best step. The temptation is to initiate chemotherapy because the patient "has cancer." The correct answer is observation. Watch and wait is standard of care for early-stage, asymptomatic CLL regardless of how high the lymphocyte count is. Treatment is initiated based on symptoms and disease complications, not the WBC number alone.

Second, confusing autoimmune hemolysis with disease progression. When a CLL patient develops sudden anemia with reticulocytosis, elevated indirect bilirubin, elevated LDH, low haptoglobin, and a positive direct Coombs test, this is warm AIHA, not worsening marrow infiltration. The treatment is corticosteroids, not CLL-directed therapy. The exam tests whether you can recognize a hemolytic pattern and attribute it to the autoimmune complication rather than reflexively escalating CLL treatment.

Third, missing Richter transformation. A stable CLL patient who suddenly develops rapidly growing lymph nodes, fever, weight loss, and a sharply rising LDH has likely undergone transformation to DLBCL. The next step is an excisional lymph node biopsy, not continued observation or intensification of CLL therapy. This transformation changes the diagnosis and treatment approach entirely.

Additional pearls worth memorizing:

• CLL is the only leukemia where you do NOT need a bone marrow biopsy for diagnosis. Flow cytometry on peripheral blood is sufficient.

• Smudge cells on the peripheral smear are a classic clue, but they are an artifact, not a diagnostic criterion. The diagnosis rests on flow cytometry.

• Del(17p)/TP53 mutation is the most important prognostic marker because it dictates treatment selection: these patients must receive targeted therapy (ibrutinib or venetoclax), as chemoimmunotherapy is ineffective.

• CLL and SLL are the same disease along a spectrum. The distinction is purely based on whether the disease is predominantly in the blood (CLL) or the lymph nodes (SLL).

• Venetoclax requires a mandatory dose ramp-up because of the risk of tumor lysis syndrome. This is a frequently tested pharmacology concept.

The core competency being tested across all CLL questions is the ability to recognize an indolent disease that demands restraint in early stages, to correctly identify its complications (autoimmune cytopenias, transformation), and to match treatment to the patient's genetic risk profile rather than applying a one-size-fits-all chemotherapy approach.